1. Periman S. Another decade, another coronavirus.N Engl J Med. 2020;382:760-762.

2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019.N Engl J Med. 2020;382:727-733.

3. Centers for Disease Control and Prevention. More Resources About COVID-19. Available athttps://www.cdc.gov/coronavirus/2019-ncov/more/index.html. Last accessed February 14, 2023.

4. Munster VJ, Koopmans M, van Doremalen N, et al. A novel coronavirus emerging in China: key questions for impact assessment.N Engl J Med. 2020;382:692-694.

5. Azhar EI, El-Kafrawy SA, Farraj SA, et al. Evidence for camel-to-human transmission of MERS Coronavirus.N Engl J Med. 2014;370:2499-2505.

6. 6. Drosten C, Meyer B, Muller MA, et al. Transmission of MERS-Coronavirus in household contacts.N Engl J Med. 2014;371:828-835.

7. Assiri A, McGeer A, Peri TM, et al. Hospital outbreak of Middle East Respiratory Syndrome Coronavirus.N Engl J Med. 2013;369:407-416.

8. World Health Organization. Coronavirus Disease (COVID-19) Pandemic. Available athttps://www.who.int/emergencies/diseases/novel-coronavirus-2019. Last accessed February 14, 2023.

9. Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet. 2020;395(10223):497-506.

10. Infectious Disease Society of America. COVID-19 Resource Center. Available athttps://www.idsociety.org/covid-19-real-time-learning-network. Last accessed February 14, 2023.

11. World Health Organization. Coronavirus Disease (COVID-19) Advice for the Public. Available athttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public. Last accessed February 14, 2023.

12. Centers for Disease Control and Prevention. COVID-19. Available athttps://www.cdc.gov/coronavirus/2019-ncov/index.html. Last accessed February 14, 2023.

13. 13. Centers for Disease Control and Prevention. Domestic Travel During COVID-19. Available athttps://www.cdc.gov/coronavirus/2019-ncov/travelers/travel-during-covid19.html. Last accessed February 14, 2023.

14. Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2, the Virus the Causes COVID-19. Available athttps://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html. Last accessed February 14, 2023.

15. Centers for Disease Control and Prevention. Clinical Care Considerations. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-index.html. Last accessed February 14, 2023.

16. U.S. Food and Drug Administration. FDA Takes Significant Step in Coronavirus Response Efforts, Issues Emergency Use Authorization for the First 2019 Novel Coronavirus Diagnostic. Available athttps://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first. Last accessed February 14, 2023.

17. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med. 2020;382:1708-1720.

18. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19) in China.Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-151.

19. van Doremalen N, Bushmaker T, Morris DH, et al. To the editor: aerosolized and surface stability of SARS-CoV-2 as compared with SARS-CoV-1.N Engl J Med. 2020;382:1564-1567.

20. 20. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19.N Engl J Med. 2020; 382:1787-1799.

21. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Clin Infect Dis. 2020;71(15):732-739.

22. Devaux CA, Rolain JM, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?Int J Antimicrob Agents. 2020;55(5):105938.

23. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases From the Chinese Center for Disease Control and Prevention.JAMA. 2020;323(13):1239-1242.

24. Centers for Disease Control and Prevention. How to Protect Yourself and Others. Available athttps://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html. Last accessed February 14, 2023.

25. Centers for Disease Control and Prevention. Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. Available athttps://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html. Last accessed February 14, 2023.

26. 26. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19.N Engl J Med. 2020;382:2327-2336.

27. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma.JAMA. 2020;323(16):1582-1589.

28. Roltgen K, Nielsen ScA, Silva O, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.Cell. 2022;185:1025-1040.

29. Ao D, Lan T, He X, et al. Sars-CoV-2 Omicron variant: immune escape and vaccine development.MedComm. 2022;3(1):e126.

30. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.Cell. 2020;181(2):271-280.

31. 31. Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2.N Engl J Med. 2020;383:590-592.

32. Pei G, Zhang Z, Peng J, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia.J Am Soc Neph. 2020;31(6):1157-1165.

33. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.JAMA. 2020;323:1061-1069.

34. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease.Circulation. 2020;141:1648-1655.

35. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19: final report.N Engl J Med. 2020;383:1813-1826.

36. 36. U.S. Food and Drug Administration. Revoked: Emergency Use Authorization for Use of Chloroquine Phosphate or Hydroxychloroquine Sulphate for Treatment of 2019 Coronavirus Disease. Available athttps://www.fda.gov/media/136534/download. Last accessed February 14, 2023.

37. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19.N Engl J Med. 2020;382:2411-2418.

38. Gandhi M, Yokie DS, Havlir DV. Asymptomatic transmission, the Achilles' heel of current strategies to control COVID-19.N Engl J Med. 2020;382:2158-2160.

39. Cannegieter S, Klok FA. COVID-19-associated coagulopathy and thromboembolic disease: commentary on an interim expert guidance.Res Pract Thromb Haemost. 2020;4(4):439-445.

40. COVID-19 coagulopathy: an evolving story.Lancet. 2020;7(6):E425.

41. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.J Thromb Haemost. 2020;18(4):844-847.

42. Helms J, Tacquard C, Severac F, et al. for the CRICS TRIGGERSEP Group. High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study.Intensive Care Med. 2020;46(6):1089-1098.

43. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19.Thrombosis Research. 2020;191:145-147.

44. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of COVID-19 in New York City.N Engl J Med. 2020;382:2372-2374.

45. Centers for Disease Control and Prevention. Information for Pediatric Healthcare Providers. Available athttps://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html. Last accessed February 14, 2023.

46. New York State Department of Health. Novel Coronavirus (COVID-19): Multisystem Inflammatory Syndrome in Children (MIS-C). Available athttps://coronavirus.health.ny.gov/multisystem-inflammatory-syndrome-children-mis-c. Last accessed February 14, 2023.

47. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic.Lancet. 2020;395(10237):P1607-P1608.

48. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicenter of the SARS-CoV-2 epidemic: an observational study.Lancet. 2020;395(10239):P1771-P1778.

49. Centers for Disease Control and Prevention. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C). Available athttps://www.cdc.gov/mis/mis-c/hcp/index.html. Last accessed February 14, 2023.

50. Qui H, Wu J, Hang L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational study.Lancet. 2020;20(6):P689-P696.

51. Gudbjartsson D, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population.N Engl J Med. 2020;382:2302-2315.

52. Danis K, Epaulard O, Bénet T, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020.Clin Infect Dis. 2020;71(15):825-832.

53. 53. Bunvavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults.JAMA. 2020;323(23):2427-2429.

54. Centers for Disease Control and Prevention. Use and Care of Masks. Available at https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/about-face-coverings.html. Last accessed February 14, 2023.

55. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.MMWR. 2020;69(24):759-765.

56. Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19.N Engl J Med. 2020;383:989-992.

57. National Institutes of Health. COVID-19 Treatment Guidelines. Available athttps://www.covid19treatmentguidelines.nih.gov. Last accessed February 14, 2023.

58. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Available at https://https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Last accessed February 14, 2023.

59. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): Health Departments, Appendices. Available athttps://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/appendix.html. Last accessed February 14, 2023.

60. 60. Burke RM, Killerby ME, Newton S, et al. Symptom profiles of a convenience sample of patients with COVID-19—United States, January–April 2020.MMWR. 2020;69:904-908.

61. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents.N Engl J Med. 2020;383:334-346.

62. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York state.N Engl J Med. 2020;383:347-358.

63. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report.N Engl J Med. 2021;384:693-704.

64. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2—preliminary report.N Engl J Med. 2020;383:1920-1931.

65. 65. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial.Lancet. 2020;396(10249):P467-P478.

66. Brooks JT, Butler JC, Redfield RR. Universal masking to prevent SARS-CoV-2 transmission—the time is now.JAMA. 2020;324(7):635-637.

67. Hendrix MJ, Wade C, Findley K, Trotman R. Absence of transmission of SARS-CoV-2 after exposure at a hair salon with universal face mask policy—Springfield, Missouri.MMWR. 2020;69(28):930-932.

68. Carfi A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19.JAMA. 2020;324:603-605.

69. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020.MMWR. 2020;69:993-998.

70. 70. Cavalcanti AB, Zampieri FG, Rosa RC, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19.N Engl J Med. 2020;383:2041-2052.

71. RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19.N Engl J Med. 2020;383(21):2030-2040.

72. National Institutes of Health. NIH Halts Clinical Trial of Hydroxychloroquine. Available athttps://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydroxychloroquine. Last accessed February 14, 2023.

73. U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Hospitalized Patients. Available athttps://www.fda.gov/media/141478/download. Last accessed February 14, 2023.

74. Biran N, Andrew I, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicenter observational study.Lancet Rheumatology. 2020;2(10):e603-e612.

75. Stauffer WM, Alpern JD, Walker PF. COVID-19 and dexamethasone: a potential strategy to avoid steroid-relatedStrongyloides hyperinfection. JAMA. 2020;324(7):623-624.

76. Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience.medRxiv. 2020;Preprint.

77. Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care system.Ann Int Med. 2020;M20-3742.

78. Kass DA. COVID-19 and obesity: a big problem?Ann Int Med. 2020;M20-5677.

79. Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2, the Virus that Causes COVID-19. Available athttps://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html. Last accessed February 14, 2023.

80. U. S. Food and Drug Administration. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorization for Medical Devices: In Vitro Diagnostics EUAs. Available at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas. Last accessed February 14, 2023.

81. Fournier J, Casanovas-Massana A, Campbell M, et al. To the editor: Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2.N Engl J Med. 2020;383:1283-1286.

82. Hanson KE, Barker AP, Hillyard DR, et al. Self-collected anterior nasal and salivary specimens versus healthcare worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2.J Clin Microbiol. 2020;58(11):e01824-e01830.

83. Centers for Disease Control and Prevention. Interim Guidelines for COVID-19 Antibody Testing. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing/antibody-tests-guidelines.html. Last accessed February 14, 2023.

84. U.S. Food and Drug Administration. EUA Authorized Serology Test Performance. Available athttps://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance. Last accessed February 14, 2023.

85. Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19.JAMA. 2020;324:131-132.

86. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults.N Engl J Med. 2020;383:2427-2438.

87. Chu DK, Aki EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systemic review and meta-analysis.Lancet. 2020;395:1973-1987.

88. Centers for Disease Control and Prevention. Ending Isolation and Precautions for People with COVID-19: Interim Guidance. Available athttps://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html. Last accessed February 14, 2023.

89. Centers for Disease Control and Prevention. Clinical Questions about COVID-19: Questions and Answers: COVID-19 Risk. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html#COVID-19-Risk. Last accessed February 14, 2023.

90. U.S. Food and Drug Administration. FDA Approves First Treatment for COVID-19. Available athttps://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. Last accessed February 14, 2023.

91. Parr JB. Time to reassess tocilizumab's role in COVID-19 pneumonia.JAMA Intern Med. 2021;181(1):12-15.

92. Pringle JC, Leikauskas J, Ransom-Kelly S, et al. COVID-19 in a correctional facility employee following multiple brief exposures to persons with COVID-19—Vermont, July–August 2020.MMWR. 2020;69(43):1569-1570.

93. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia.N Engl J Med. 2021;384:619-629.

94. 94. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19.N Engl J Med. 2021;384:229-237.

95. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab. Available athttps://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab. Last accessed February 14, 2023.

96. U.S. Food and Drug Administration. Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of Casirivimab and Imdevimab. Available athttps://www.fda.gov/media/145611/download. Last accessed February 14, 2023.

97. Krammer F. SARS-CoV-2 vaccines in development.Nature. 2020;586:516-527.

98. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.N Engl J Med. 2020;383:2603-2615.

99. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.N Engl J Med. 2021;384:403-416.

100. 100. Dooling K, Marin M, Wallace M, et. al. The Advisory Committee on Immunization Practices' updated interim recommendation for allocation of COVID-19 vaccine—United States, December 2020.MMWR. 2021;69:1657-660.

101. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html. Last accessed February 14, 2023.

102. Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines.N Engl J Med. 2021;384:643-649.

103. Centers for Disease Control and Prevention. COVID-19 Vaccination, Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. Available athttps://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html. Last accessed February 14, 2023.

104. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2. Available athttps://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/masking-science-sars-cov2.html. Last accessed February 14, 2023.

105. Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries.J Am Acad Dermatol. 2020;83:486-492.

106. Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries.J Am Acad Dermatol. 2020;83:1118-1129.

107. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–October 3, 2020.MMWR. 2020;69:1641-1647.

108. Havervall S, Rosell A, Phillipson M. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers.JAMA. 2021;325(19):2015-2016.

109. Libster R, Marc GP, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults.N Engl J Med. 2021;384:610-618.

110. Oliver SE, Gargano JW, Scobie H, et al. The Advisory Committee on Immunization Practices' interim recommendation for use of Janssen COVID-19 vaccine—United States, February 2021.MMWR. 2021;70:329-332.

111. Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.Lancet. 2021;397:1057-1058.

112. Lustig Y, Nemer I, Kliker L, et al. Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2.N Engl J Med. 2021;384(25):2453-2454.

113. Centers for Disease Control and Prevention. V-Safe After Vaccination Health Checker. Available athttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html. Last accessed February 14, 2023.

114. Blumenthal KG, Freeman EE, Saff RR, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2.N Engl J Med. 2021;384:1273-1277.

115. Shamier MC, Tostmann A, Bogers S, et al. Virologic Characteristics of SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers. Available at https://ncrc.jhsph.edu/research/virological-characteristics-of-sars-cov-2-vaccine-breakthrough-infections-in-health-care-workers/. Last accessed February 14, 2023.

116. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland.N Engl J Med. 2020;383: 1724-1734.

117. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers.N Engl J Med. 2021;384:533-540.

118. Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-positive individuals in Denmark in 2020: a population-level observational study.Lancet. 2021;397(10280):1204-1212.

119. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed up to 8 months after infection.Science. 2021;371(6529):eabf4063.

120. Worobey M, Levy JI, Serrano LM, et al. The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic.Science. 2022;377(6609):951-959.

121. Barouch DH. Covid-19 vaccines: Immunity, variants, boosters.N Engl J Med. 2022;387:1011-1020.

122. Centers for Disease Control and Prevention. COVID-19 Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments. Available athttps://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/surface-transmission.html. Last accessed February 14, 2023.

123. 123. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. Available at https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html. Last accessed February 14, 2023.

124. Centers for Disease Control and Prevention. COVID Data Tracker Weekly Review. Available athttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html. Last accessed February 14. 2023.

125. Tarke A, Sidney J, Methot N, et al. Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees.bioRxiv. 2021; [Epub ahead of print].

126. Redd AD, Nardin A, Kared H, et al. CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants.Open Forum Infectious Diseases. 2021; [Epub ahead of print].

127. U. S. Food and Drug Administration. Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. Available athttps://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine. Last accessed February 14, 2023.

128. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.N Engl J Med. 2021;384(22):2092-2101.

129. Schultz NH, Sorvoll IH, Michelsen AE, et al. Brief report: thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.N Engl J Med. 2021;384(22):2124-2130.

130. Hunter PR. Editorial: thrombosis after covid-19 vaccination.BMJ. 2021;373:n958.

131. Centers for Disease Control and Prevention. Stay Up to Date with COVID-19 Vaccines Including Boosters. Available at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html. Last accessed February 14, 2023.

132. Centers for Disease Control and Prevention. Delta Variant: What We Know About the Science. Available at https://stacks.cdc.gov/view/cdc/108671. Last accessed February 14, 2023.

133. Le Page M, Thomson H, Vaughan A, Wilson C. Getting to grips with long COVID.New Sci. 2021;250:10-13.

134. Becker JH, Lin JJ, Doernberg M, et al. Assessment of cognitive function in patients after COVID-19 infection.JAMA Netw Open. 2021;4(10):e2130645.

135. Say D, Crawford N, McNab S, et al. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease.Lancet: Child & Adolescent Health. 2021;5(6):e22-e23.

136. American Academy of Pediatrics. Children and COVID-19: State-Level Data Report. Available athttps://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report. Last accessed February 14, 2023.

137. Centers for Disease Control and Prevention. COVID Data Tracker: Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States. Available at https://covid.cdc.gov/covid-data-tracker/#mis-national-surveillance. Last accessed February 14, 2023.

138. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study.Am J Obstet Gynecol. 2021;225(3):303.e1-303.e17.

139. Centers for Disease Control and Prevention. V-safe COVID-19 Vaccine Pregnancy Registry. Available athttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafepregnancyregistry.html. Last accessed February 14, 2023.

140. Zauche LH, Wallace B, Smoots AN, et al. To the editor: receipt of mRNA vaccines and risk of spontaneous abortion.NEJM. 2021;385:1533-1535.

141. Magnus MC, Gjessing HK, Eide HN, et al. To the editor: COVID-19 vaccination during pregnancy and first-trimester miscarriage.NEJM. 2021;385:2008-2010.

142. 142. Academy of Breastfeeding Medicine. ABM Statement: Considerations for COVID-19 Vaccination in Lactation. Available athttps://abm.memberclicks.net/abm-statement-considerations-for-covid-19-vaccination-in-lactation. Last accessed February 14, 2023.

143. Golan Y, Prahi M, Cassidy A, et al. Evaluation of messenger RNA from COVID-19 BTN162b2 and mRNA-1273 vaccines in human milk.JAMA Pediatr. 2021;10:1069-1071.

144. The American College of Obstetricians and Gynecologists. Statement of Strong Medical Consensus for Vaccination of Pregnant Individuals Against COVID-19. Available athttps://www.acog.org/news/news-releases/2021/08/statement-of-strong-medical-consensus-for-vaccination-of-pregnant-individuals-against-covid-19. Last accessed February 14, 2023.

145. Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNtech and Moderna): update from the Advisory Committee on Immunization Practices—United States, July 2021.MMWR. 2021;70:1094-1099.

146. Barda N, Dagan N, Shiomo YB, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nation-wide setting.N Eng J Med. 2021;385:1078-1090.

147. U.S. Department of Health and Human Services. Statement Following CDC ACIP Meeting from Nations Leading Doctors, Nurses, Pharmacists and Public Health Leaders on Benefits of Vaccination. Available at https://www.aap.org/en/news-room/news-releases/aap/2021/statement-following-cdc-acip-meeting-from-nations-leading-doctors-nurses-and-public-health-leaders. Last accessed February 14, 2023.

148. Delahoy MJ, Ujamaa D, Whitaker M, et al. Hospitalizations associated with COVID-19 among children and adolescents—COVID-NET, 14 states, March 1, 2020–August 14, 2021.MMWR. 2021;70:1255-1260.

149. Seasely AR, Blanchard CT, Arora N, et al. Maternal and perinatal outcomes associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) variant.Obstetrics & Gynecology. 2021;138(6):842-844.

150. Morris RS. SARS-CoV-2 spike protein seropositivity from vaccination or infection does not cause sterility.Amer Soc Reproduct Med, F & S Rep. 2021;2(3):253-255.

151. Gonzalez DC, Nassau DE, Khodamoradi K, et al. Sperm parameters before and after COVID-19 mRNA vaccination.JAMA. 2021;326:273-274.

152. Hezavehei M, Shokoohian B, Nasr-Esfahani MH, et al. Possible male reproduction complications after Coronavirus pandemic.Cell J. 2021;23:382-388.

153. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization.N Engl J Med. 2021;385:2132-2139.

154. Centers for Disease Control and Prevention. COVID-19 vaccine breakthrough infections reported to CDC—United States, January 1–April 30, 2021.MMWR. 2021;70:792-793.

155. Flaxman S, Whittaker C, Semenova E, et al. Assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US.JAMA Netw Open. 2023;6(1):e2253590.

156. Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.Science. 2021;374(6572):abm0829.

157. Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity—nine states, January–September 2021.MMWR. 2021;70(44):1539-1544.

158. Griffin JB, Haddix M, Danza P, et al. SARS-CoV-2 infections and hospitalizations among persons aged >16 years, by vaccination status—Los Angeles County, May 1–July 25, 2021.MMWR. 2021;70(34):1170-1176.

159. Richter DR, Guasti L, Koehler F, et al. Late phase of COVID-18 pandemic in general cardiology: a position paper of the ESC Council for Cardiology Practice.ESC Heart Failure. 2021;8:3483-3494.

160. Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19.Nat Med. 2022;28:583-590.

161. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study.Lancet Diabetes & Endocrinology. 2022;10(5): 311-321.

162. Bradley RE, Ponsford MJ, Scurr MJ, et al. Therapeutic vaccination: a case report.J Clin Immun. 2022;42:32-35.

163. Marks KJ, Whitaker M, Agathis NT, et al. Hospitalization of infants and children aged 0-4 years with laboratory-confirmed COVID-19—COVID-NET, 14 states, March 2020–February 2022.MMWR. 2022;71(11):429-436.

164. Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years—United States, July–December 2021.MMWR. 2022;71(2): 52-58.

165. Gottlieb RL, Vaca CE, Peredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients.N Engl J Med. 2022;386:305-315.

166. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.N Engl J Med. 2022;386:1397-1408.

167. Centers for Disease Control and Prevention, Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19. Available athttps://emergency.cdc.gov/han/2021/han00449.asp. Last accessed February 14, 2023.

168. Yemple C, Hoang R, Hendrickson RG. Toxic effects of ivermectin use associated with prevention and treatment of Covid-19.N Engl J Med. 2021;385:2197-2198.

169. 169. Lopez-Medina E, Lopez P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19.JAMA. 2021;325:1426-1435.

170. Reis G, Silva E, Silva D, et al. Effect of early treatment with ivermectin among patients with Covid-19.N Engl J Med. 2022;386:1721-1731.

171. Lim SCL, Hor CP, Tay KH, et al. Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial.JAMA Intern Med. 2022;182(4):426-435.

172. Tenforde MW, Self WH, Gaglani M, et al. Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death—United States, March 2021–January 2022.MMWR. 2022;71(12):459-465.

173. Block JP, Borhmer TK, Forrest CB, et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination—PCORnet, United States, January 2021–January 2022.MMWR. 2022;71(14);517-523.

174. 174. Nordstrom P, Ballin M, Nordstrom A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalization in individuals with natural and hybrid immunity: a retrospective study, total population cohort study in Sweden.Lancet Infect Dis. 2022;22(6):781-790.

175. U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of Baricitinib. Available athttps://www.fda.gov/media/143823/download. Last accessed February 14, 2023.

176. Centers for Disease Control and Prevention. COVID-19 Rebound After Paxlovid Treatment. Available athttps://emergency.cdc.gov/han/2022/pdf/CDC_HAN_467.pdf. Last accessed February 14, 2023.

177. Allotey J, Chatterjee S, Kew T, et al. SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis.BMJ. 2022;376:e067696.

178. Konstantinidou AE, Angelidou S, Havaki S, et al. Stillbirth due to SARS-CoV-2 placentitis without evidence of intrauterine transmission to fetus: association and maternal risk factors.Ultrasound Obstet Gynecol. 2022;59:813-822.

179. U.S. Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. Available at https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-applications-inds-cber-regulated-products/recommendations-investigational-covid-19-convalescent-plasma. Last accessed February 14, 2023.

180. McConeghy KW, White EM, Blackman C, et al. Effectiveness of a second COVID-19 vaccine booster dose against infection, hospitalization, or death among nursing home residents—19 states, March 29–July 25, 2022.MMWR. 2022;71:1235-1238.

181. Zou J, Kurhade C, Patel S, et al. Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine.N Engl J Med. 2023; [Epub ahead of print].

182. Link-Gelles R, Ciesla AA, Fleming-Dutra KE, et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection: Increasing Community Access to Testing Program, United States, September–November 2022.MMWR. 2022;71:1526-1530.

183. Lin D-Y, Xu Y, Gu Y, et al. Letter: Effectiveness of bivalent boosters against severe Omicron infection.N Engl J Med. 2023; (Epub ahead of print).

184. Arbel, Ronen, Peretz, et al. Effectiveness of bivalent mRNA vaccine in preventing severe COVID-19 outcomes: an observational cohort study.Lancet. 2023; [Epub ahead of print].

185. Link-Gelles R, Ciesla AA, Roper LE, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5- and XBB/XBB.1.5-related sublineages among immunocompetent adults – Increasing Community Access to Testing Program, United States, December 2022–January 2023.MMWR. 2023;72(5);119-124.